Literature DB >> 9441781

An evaluation of prognostic factors in uterine carcinosarcoma.

R R Nordal1, G B Kristensen, A E Stenwig, J M Nesland, E O Pettersen, C G Trope.   

Abstract

The traditional clinical and histopathological prognostic variables and DNA ploidy were analyzed in 46 patients with histologically verified uterine carcinosarcoma. Twenty-three tumors were of the homologous and 23 of the heterologous type. Evaluable flow cytometric DNA histograms from paraffin-embedded tumor tissue were obtained in 39 patients. The overall 5-year cancer related survival was 31%. All tumors were of high malignancy grade. In univariate analysis of survival, extrauterine spread of tumor (P = 0.007), age (P = 0.008), and tumor diameter (P = 0.04) obtained statistical significance. Tumors with components of serous or clear cell carcinomas had a less favorable prognosis (P = 0.017). There was no difference in survival between patients with homologous and heterologous tumors (P = 0.39). Mitotic count, vessel invasion, and DNA ploidy did not obtain prognostic significance. In Cox multivariate analysis, extrauterine spread of tumor (P = 0.004) and age (P = 0.004) were found to be the most important prognostic factors followed by content of serous or clear cell carcinoma components (P = 0.027).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9441781     DOI: 10.1006/gyno.1997.4875

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

1.  Serum CA125 predicts extrauterine disease and survival in uterine carcinosarcoma.

Authors:  Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2007-10-23       Impact factor: 5.482

Review 2.  Tamoxifen in breast cancer ipse dixit in uterine malignant mixed Müllerian tumor and sarcoma-A report of 8 cases and review of the literature.

Authors:  Ana Luisa Cardoso Vasconcelos; Beatriz Nunes; Catarina Duarte; Vera Mendonça; Joana Ribeiro; Marília Jorge; Isabel Monteiro Grillo
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-12

3.  Comparison of survival outcomes between patients with malignant mixed mullerian tumors and high-grade endometrioid, clear cell, and papillary serous endometrial cancers.

Authors:  Ashley Sinclair Felix; Roslyn A Stone; Robert Bowser; Mamatha Chivukula; Robert P Edwards; Joel L Weissfeld; Faina Linkov
Journal:  Int J Gynecol Cancer       Date:  2011-07       Impact factor: 3.437

Review 4.  Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

Authors:  W G McCluggage
Journal:  J Clin Pathol       Date:  2002-05       Impact factor: 3.411

5.  Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.

Authors:  Tadao Takano; Takeo Otsuki; Hideki Tokunaga; Masafumi Toyoshima; Hiroki Utsunomiya; Satoru Nagase; Hitoshi Niikura; Kiyoshi Ito; Nobuo Yaegashi; Hidekazu Yamada; Toru Tase; Masahiro Kagabu; Tadahiro Shoji; Toru Sugiyama; Naoki Sato; Toshio Fujimoto; Yukihiro Terada; Kenji Nakahara; Hirohisa Kurachi; Yoshihito Yokoyama; Hideki Mizunuma; Shu Soeda; Hiroshi Nishiyama; Takashi Matsumoto; Shinya Sato; Muneaki Shimada; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2014-01-07       Impact factor: 3.402

6.  The role of liver-directed surgery in patients with hepatic metastasis from a gynecologic primary carcinoma.

Authors:  Sarah I Kamel; Mechteld C de Jong; Richard D Schulick; Teresa P Diaz-Montes; Christopher L Wolfgang; Kenzo Hirose; Barish H Edil; Michael A Choti; Robert A Anders; Timothy M Pawlik
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

7.  Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.

Authors:  Theodore M Brasky; Ashley S Felix; David E Cohn; D Scott McMeekin; David G Mutch; William T Creasman; Premal H Thaker; Joan L Walker; Richard G Moore; Shashikant B Lele; Saketh R Guntupalli; Levi S Downs; Christa I Nagel; John F Boggess; Michael L Pearl; Olga B Ioffe; Kay J Park; Shamshad Ali; Louise A Brinton
Journal:  J Natl Cancer Inst       Date:  2017-03-01       Impact factor: 13.506

8.  Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.

Authors:  Matthew A Powell; Virginia L Filiaci; Martee L Hensley; Helen Q Huang; Kathleen N Moore; Krishnansu S Tewari; Larry J Copeland; Angeles A Secord; David G Mutch; Alessandro Santin; David P Warshal; Nick M Spirtos; Paul A DiSilvestro; Olga B Ioffe; David S Miller
Journal:  J Clin Oncol       Date:  2022-01-10       Impact factor: 50.717

9.  [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors].

Authors:  L-C Horn; M Dallacker; K Bilek
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

10.  Evaluation of postoperative chemotherapy in patients with uterine carcinosarcoma: a retrospective survey of the Tohoku Gynecologic Cancer Unit.

Authors:  Ai Otsuki; Takeo Otsuki; Hideki Tokunaga; Hitoshi Niikura; Satoru Nagase; Takashi Sugiyama; Masafumi Toyoshima; Hiroki Utsunomiya; Yoshihito Yokoyama; Hideki Mizunuma; Naoki Sato; Yukihiro Terada; Tadahiro Shoji; Toru Sugiyama; Kenji Nakahara; Tsuyoshi Ohta; Hidekazu Yamada; Toru Tase; Hiroshi Nishiyama; Keiya Fujimori; Tadao Takano; Fumiaki Takahashi; Yoh Watanabe; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2014-07-18       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.